U.S. Patent Disclosures

No Abstract

Novosom AG, of Halle, Germany, received U.S. Patent No. 7,371,404, titled "Amphoteric liposomes and their use." It covers Smarticles, which are fully charged reversible liposomes for the in vivo delivery of nucleotides such as siRNA or antisense to targeted cells.

Oncolytics Biotech Inc., of Calgary, Alberta, was granted U.S. Patent No. 7,374,752, titled "Reovirus for the Treatment of Cellular Proliferative Disorders," which covers pharmaceutical compositions comprising various recombinant reoviruses.